Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$37 Mln
P/E Ratio
--
P/B Ratio
7.83
Industry P/E
--
Debt to Equity
-1.68
ROE
-4.17 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-6.15
CFO
$-143.80 Mln
EBITDA
$-162.29 Mln
Net Profit
$-110.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Clene Inc (CLNN)
| -16.97 | -8.33 | 1.13 | -44.89 | -57.34 | -53.65 | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Clene Inc (CLNN)
| -11.41 | -70.00 | -75.61 | -54.50 | -13.99 | 5.85 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.43 | 10,257.64 | 20.82 | 23.13 | |
| 33.74 | 13,384.89 | -- | -28.77 | |
| 109.59 | 11,042.16 | 33.66 | 14.16 | |
| 75.85 | 9,430.55 | 41.53 | 19.71 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various... clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Address: 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121 Read more
CEO, President & Director
Mr. Robert Etherington MBA
CEO, President & Director
Mr. Robert Etherington MBA
Headquarters
Salt Lake City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Clene Inc (CLNN) stood at $ 55 Mln as on 30-Sep-24
The share price of Clene Inc (CLNN) is $4.41 (NASDAQ) as of 18-Mar-2025 13:39 EDT. Clene Inc (CLNN) has given a return of -57.34% in the last 3 years.
Clene Inc (CLNN) has a market capitalisation of $ 37 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Clene Inc (CLNN) is 7.83 times as on 17-Mar-2025, a 191% premium to its peers’ median range of 2.69 times.
Since, TTM earnings of Clene Inc (CLNN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Clene Inc (CLNN) and enter the required number of quantities and click on buy to purchase the shares of Clene Inc (CLNN).
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. Address: 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121
The CEO & director of Mr. Robert Etherington MBA. is Clene Inc (CLNN), and CFO & Sr. VP is Mr. Robert Etherington MBA.
There is no promoter pledging in Clene Inc (CLNN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Clene Inc. (CLNN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-7428.98
|
|
Net Margin(%)
|
-8556.77
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Clene Inc (CLNN) was $0 Mln.
$-0.15
(
